Literature DB >> 10679507

Amlodipine, enalapril, and dependent leg edema in essential hypertension.

R Pedrinelli1, G Dell'Omo, E Melillo, M Mariani.   

Abstract

Calcium channel blockers (CCBs) blunt postural skin vasoconstriction, an autoregulatory mechanism that minimizes gravitational increases in capillary pressure and avoids fluid extravasation when standing. To evaluate the dose-response relation between this pharmacological interference and dependent edema, a frequent side effect of CCBs during antihypertensive treatment, skin blood flow (laser Doppler flowmetry) at the dorsum of the foot, both supine and with the limb passively placed 50 cm below the heart level, and leg weight (Archimedes principle) were measured at baseline, during increasing doses of the dihydropyridine amlodipine (5 and 10 mg UID each for 2 weeks), and after drug withdrawal in 10 hypertensive men. Because angiotensin-converting enzyme inhibitors may attenuate ankle swelling by CCBs, those parameters were evaluated according to a similar design during amlodipine (10 mg UID) and enalapril (20 mg UID) combined (n=10). As a control, the effect of enalapril monotherapy (10 and 20 mg UID for 2 weeks each) was evaluated in a third series of patients (n=8). Amlodipine (5 mg UID) increased leg weight without modifying postural vasoconstriction (the percent skin blood flow decrease from horizontal to dependent position), which indicates that extravascular fluid shift was independent of postural skin vasoconstriction. At 10 mg UID, however, amlodipine blunted postural vasoconstriction and increased leg weight further, which suggests that skin blood flow autoregulation limited additional fluid transfer. Both parameters normalized after drug withdrawal. Enalapril per se did not affect cutaneous vasomotion or leg weight but reduced the amount of dependent fluid extravasation by the CCB despite a persistent antagonism for postural vasoconstrictor responses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10679507     DOI: 10.1161/01.hyp.35.2.621

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  10 in total

1.  The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis.

Authors:  Punnaka Pongpanich; Pasvich Pitakpaiboonkul; Kullaya Takkavatakarn; Kearkiat Praditpornsilpa; Somchai Eiam-Ong; Paweena Susantitaphong
Journal:  Int Urol Nephrol       Date:  2018-10-15       Impact factor: 2.370

2.  Inhibition of smooth muscle myosin as a novel therapeutic target for hypertension.

Authors:  Xin Zhao; David Ho; Patricio Abarzúa; Sunil K Dhar; Xi Wang; Zhiheng Jia; Malar Pannirselvam; David J Morgans; Fady I Malik; Stephen F Vatner
Journal:  J Pharmacol Exp Ther       Date:  2011-07-22       Impact factor: 4.030

Review 3.  Combination drug treatment of hypertension: have we come full circle?

Authors:  Addison A Taylor
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

4.  Human lymphatic vessel contractile activity is inhibited in vitro but not in vivo by the calcium channel blocker nifedipine.

Authors:  Niklas Telinius; Sheyanth Mohanakumar; Jens Majgaard; Sukhan Kim; Hans Pilegaard; Einar Pahle; Jørn Nielsen; Marc de Leval; Christian Aalkjaer; Vibeke Hjortdal; Donna Briggs Boedtkjer
Journal:  J Physiol       Date:  2014-08-28       Impact factor: 5.182

5.  Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects.

Authors:  C Kollmannsberger; D Soulieres; R Wong; A Scalera; R Gaspo; G Bjarnason
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

6.  Comparison of amlodipine with cilnidipine on antihypertensive efficacy and incidence of pedal edema in mild to moderate hypertensive individuals: A prospective study.

Authors:  Prabhakar Adake; H S Somashekar; P K Mohammed Rafeeq; Dilshad Umar; Bahija Basheer; Kusai Baroudi
Journal:  J Adv Pharm Technol Res       Date:  2015 Apr-Jun

7.  A Retrospective, Observational, EMR-Based Real-World Evidence Study to Assess the Incidence of Pedal Edema in Essential Hypertensive Patients on Amlodipine or Cilnidipine.

Authors:  Jamshed Dalal; J P Sawhney; P B Jayagopal; P K Hazra; Mohammed Yunus Khan; Kumar Gaurav; Colette Pinto; Amey Mane; Sachin Rao; Madhur Jain
Journal:  Int J Hypertens       Date:  2022-02-23       Impact factor: 2.420

8.  Efficacy and tolerability of initial high vs low doses of S-(-)-amlodipine in hypertension.

Authors:  Qi Chen; Qi-Fang Huang; Yuan-Yuan Kang; Shao-Kun Xu; Chang-Yuan Liu; Yan Li; Ji-Guang Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-05-30       Impact factor: 3.738

Review 9.  Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer.

Authors:  Nathalie Theou-Anton; Sandrine Faivre; Chantal Dreyer; Eric Raymond
Journal:  Drug Saf       Date:  2009       Impact factor: 5.228

Review 10.  Calcium channel blocker-related periperal edema: can it be resolved?

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Jul-Aug       Impact factor: 3.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.